Impact of polypharmacy phenogroups on different heart failure phenotypes in patients with chronic heart failure: a retrospective examination of real-world cohort
In patients with chronic Heart failure, guideline directed polypharmacy was associated with improved survival, particularly in HFpEF and HFmrEF phenotypes. However, non-heart failure-related polypharmacy is associated with worse outcomes including ICU admissions, necessitating need for targeted interventions for this group of patients.
Authors
- Ahmad Radaideh (ORCID: https://orcid.org/0000-0003-1556-9972)
- Mohammed Danjuma (ORCID: https://orcid.org/0000-0003-2198-5278)
- Ahmed Tarek Aboughalia (ORCID: https://orcid.org/0000-0002-4481-5944)
- Abdul Haseeb Said Wali
- Joud Abuodeh
- Aseel Sukik (ORCID: https://orcid.org/0000-0002-3725-9281)
- Abdel-Naser Y Elzouki (ORCID: https://orcid.org/0000-0002-9132-1752)
- Oyelola A. Adegboye (ORCID: https://orcid.org/0000-0002-9793-8024)
- Osama El‐Sayed
- Mohammed Amer (ORCID: https://orcid.org/0000-0002-8735-6098)
Institutions
- Charles Darwin University (AU)
- Menzies School of Health Research (AU)
- NHS Grampian (GB)
- Hamad General Hospital (QA)
- Dr Gray's Hospital (GB)
- Weill Cornell Medical College in Qatar (QA)
- Hamad Medical Corporation (QA)
- Qatar University (QA)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-06
- DOI
- https://doi.org/10.3389/fphar.2025.1526112
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Qatar National Library